Effects of Raloxifene on Bone Metabolism in Hemodialysis Patients


avatar Jun Iwamoto 1 , *

Institute for Integrated Sports Medicine, Keio University School of Medicine, Tokyo, Japan

how to cite: Iwamoto J. Effects of Raloxifene on Bone Metabolism in Hemodialysis Patients. Int J Endocrinol Metab. 2012;10(3): 573-575. https://doi.org/10.5812/ijem.5367.


  • 1.

    Saito O, Saito T, Asakura S, Akimoto T, Inoue M, Ando S, et al. Effects of raloxifene on bone metabolism in hemodialysis patients with type 2 diabetes. Int J Endocrinol Metab. 2012;10:464-9. https://doi.org/10.5812/ijem.3794.

  • 2.

    Iwamoto J, Sato Y, Takeda T, Matsumoto H. Bone quality and vitamin K2 in type 2 diabetes: review of preclinical and clinical studies. Nutr Rev. 2011;69(3):162-7. [PubMed ID: 21348880]. https://doi.org/10.1111/j.1753-4887.2011.00380.x.

  • 3.

    Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Yano S, Sugimoto T. Serum insulin-like growth factor-I level is associated with the presence of vertebral fractures in postmenopausal women with type 2 diabetes mellitus. Osteoporos Int. 2007;18(12):1675-81. [PubMed ID: 17632742]. https://doi.org/10.1007/s00198-007-0430-0.

  • 4.

    Kanazawa I, Yamaguchi T, Yamamoto M, Yamauchi M, Yano S, Sugimoto T. Serum osteocalcin/bone-specific alkaline phosphatase ratio is a predictor for the presence of vertebral fractures in men with type 2 diabetes. Calcif Tissue Int. 2009;85(3):228-34. [PubMed ID: 19641839]. https://doi.org/10.1007/s00223-009-9272-4.

  • 5.

    Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA. 1999;282(7):637-45. [PubMed ID: 10517716]. https://doi.org/10.1001/jama.282.7.637.

  • 6.

    Johnell O, Kanis JA, Black DM, Balogh A, Poor G, Sarkar S, et al. Associations between baseline risk factors and vertebral fracture risk in the Multiple Outcomes of Raloxifene Evaluation (MORE) Study. J Bone Miner Res. 2004;19(5):764-72. [PubMed ID: 15068500]. https://doi.org/10.1359/jbmr.040211.

  • 7.

    Fried LF, Biggs ML, Shlipak MG, Seliger S, Kestenbaum B, Stehman-Breen C, et al. Association of kidney function with incident hip fracture in older adults. J Am Soc Nephrol. 2007;18(1):282-6. [PubMed ID: 17167115]. https://doi.org/10.1681/ASN.2006050546.

  • 8.

    Kinsella S, Chavrimootoo S, Molloy MG, Eustace JA. Moderate chronic kidney disease in women is associated with fracture occurrence independently of osteoporosis. Nephron Clin Pract. 2010;116(3):c256-62. [PubMed ID: 20606487]. https://doi.org/10.1159/000317207.

  • 9.

    Nickolas TL, Leonard MB, Shane E. Chronic kidney disease and bone fracture: a growing concern. Kidney Int. 2008;74(6):721-31. [PubMed ID: 17005938]. https://doi.org/10.1681/ASN.2005111194.

  • 10.

    Nickolas TL, McMahon DJ, Shane E. Relationship between moderate to severe kidney disease and hip fracture in the United States. J Am Soc Nephrol. 2006;17(11):3223-32. [PubMed ID: 17005938]. https://doi.org/10.1681/ASN.2005111194.

  • 11.

    West SL, Lok CE, Jamal SA. Fracture Risk Assessment in Chronic Kidney Disease, Prospective Testing Under Real World Environments (FRACTURE): a prospective study. BMC Nephrol. 2010;11:17. [PubMed ID: 20727179]. https://doi.org/10.1186/1471-2369-11-17.

  • 12.

    Pitts TO, Piraino BH, Mitro R, Chen TC, Segre GV, Greenberg A, et al. Hyperparathyroidism and 1,25-dihydroxyvitamin D deficiency in mild, moderate, and severe renal failure. J Clin Endocrinol Metab. 1988;67(5):876-81. [PubMed ID: 3182962]. https://doi.org/10.1210/jcem-67-5-876.

  • 13.

    Jamal SA, West SL, Miller PD. Bone and kidney disease: diagnostic and therapeutic implications. Curr Rheumatol Rep. 2012;14(3):217-23. [PubMed ID: 22350608]. https://doi.org/10.1007/s11926-012-0243-9.

  • 14.

    Ishani A, Blackwell T, Jamal SA, Cummings SR, Ensrud KE. The effect of raloxifene treatment in postmenopausal women with CKD. J Am Soc Nephrol. 2008;19(7):1430-8. [PubMed ID: 18400939]. https://doi.org/10.1681/ASN.2007050555.

  • 15.

    Melamed ML, Blackwell T, Neugarten J, Arnsten JH, Ensrud KE, Ishani A, et al. Raloxifene, a selective estrogen receptor modulator, is renoprotective: a post-hoc analysis. Kidney Int. 2011;79(2):241-9. [PubMed ID: 20927038]. https://doi.org/10.1038/ki.2010.378.

  • 16.

    Janghorbani M, Van Dam RM, Willett WC, Hu FB. Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol. 2007;166(5):495-505. [PubMed ID: 17575306]. https://doi.org/10.1093/aje/kwm106.

  • 17.

    Adami S. Bone health in diabetes: considerations for clinical management. Curr Med Res Opin. 2009;25(5):1057-72. [PubMed ID: 19292601]. https://doi.org/10.1185/03007990902801147.

  • 18.

    Saito M, Marumo K, Soshi S, Kida Y, Ushiku C, Shinohara A. Raloxifene ameliorates detrimental enzymatic and nonenzymatic collagen cross-links and bone strength in rabbits with hyperhomocysteinemia. Osteoporos Int. 2010;21(4):655-66. [PubMed ID: 19484165]. https://doi.org/10.1007/s00198-009-0980-4.